



## **Aclaris Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference**

September 20, 2023

WAYNE, Pa., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that members of the Aclaris management team will participate in a fireside chat during the 2023 Cantor Global Healthcare Conference on Tuesday, September 26, 2023 at 10:30 AM ET, in New York, NY.

A webcast of the fireside chat may be accessed through the "Events" page of the "Investors" section of Aclaris' website, [www.aclaristx.com](http://www.aclaristx.com). The webcast will be archived for at least 30 days on the Aclaris website.

### **About Aclaris Therapeutics, Inc.**

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of drug candidates powered by a robust R&D engine exploring protein kinase regulation. For additional information, please visit [www.aclaristx.com](http://www.aclaristx.com).

### **Aclaris Therapeutics Contact:**

Robert A. Doody Jr.  
Vice President, Investor Relations  
484-639-7235  
[rdoody@aclariastx.com](mailto:rdoody@aclariastx.com)



Source: Aclaris Therapeutics, Inc.